| 57.87 1.54 (2.73%) | 09-12 12:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 68.59 | 1-year : | 80.12 |
| Resists | First : | 58.72 | Second : | 68.59 |
| Pivot price | 56.54 |
|||
| Supports | First : | 52.21 | Second : | 48.19 |
| MAs | MA(5) : | 56.1 |
MA(20) : | 55.83 |
| MA(100) : | 45.57 |
MA(250) : | 43.92 |
|
| MACD | MACD : | 1.8  |
Signal : | 2.2 |
| %K %D | K(14,3) : | 58.4 |
D(3) : | 54.5 |
| RSI | RSI(14): 67.1 |
|||
| 52-week | High : | 58.72 | Low : | 31.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RARE ] has closed below upper band by 19.4%. Bollinger Bands are 57.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 56.56 - 56.83 | 56.83 - 57.07 |
| Low: | 54.29 - 54.6 | 54.6 - 54.87 |
| Close: | 55.85 - 56.35 | 56.35 - 56.77 |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Wed, 11 Sep 2024
TD Asset Management Inc Sells 71,276 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Sun, 08 Sep 2024
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Boosted by Candriam S.C.A. - MarketBeat
Thu, 05 Sep 2024
Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now - Yahoo Finance
Thu, 29 Aug 2024
Ultragenyx to Participate in Investor Conferences in September - StockTitan
Thu, 25 Jul 2024
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update - StockTitan
Fri, 14 Jun 2024
Marin County’s Ultragenyx seeks to raise $350 million to advance rare-disease drugs - The Santa Rosa Press Democrat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 92 (M) |
| Shares Float | 89 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 98.6 (%) |
| Shares Short | 3,850 (K) |
| Shares Short P.Month | 4,360 (K) |
| EPS | -7.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.69 |
| Profit Margin | -121.6 % |
| Operating Margin | -79.2 % |
| Return on Assets (ttm) | -23.5 % |
| Return on Equity (ttm) | -208.5 % |
| Qtrly Rev. Growth | 35.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 5.22 |
| EBITDA (p.s.) | -5.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -469 (M) |
| Levered Free Cash Flow | -276 (M) |
| PE Ratio | -7.97 |
| PEG Ratio | -0.3 |
| Price to Book value | 12.21 |
| Price to Sales | 10.99 |
| Price to Cash Flow | -11.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|